Literature DB >> 21145099

A comparison of pure adenocarcinoma and squamous cell carcinoma of the cervix after radical hysterectomy in stage IB-IIA.

Yoo-Young Lee1, Chel Hun Choi, Tae-Joong Kim, Jeong-Won Lee, Byoung-Gie Kim, Je-Ho Lee, Duk-Soo Bae.   

Abstract

OBJECTIVE: This study was designed to investigate the survival difference between pure adenocarcinoma (AC) and squamous cell carcinoma (SCC) in early cervical cancer (FIGO stage IB-IIA) after radical hysterectomy with or without adjuvant therapy performed at a single institution.
METHODS: Patients with AC or SCC between November 1994 and September 2007 at the Samsung Medical Center, Sungkyunkwan University School of Medicine in Seoul, Korea were evaluated.
RESULTS: Among the 775 patients, 636 patients had SCC, and 139 patients had pure AC. In basal characteristics, preoperative FIGO stage, adjuvant therapy after surgery, as well as chemotherapeutic regimens, were not different between the two groups. However, the median age was about 5 years younger in pure AC patients than in SCC patients (44 years vs. 49 years, P=.001). In the comparison of pathological findings after surgery between the two groups, there were no differences between the two groups, except for LVSI status. The recurrence rate was higher in the pure AC group than in the SCC group (SCC; 36/636; 5.7%, AC; 20/139; 14.4%, P=<0.001, respectively). The pure AC group had a higher recurrence rate in hematogenous/distant areas than the SCC group (SCC: 8/36; 22.2%, AC; 9/20; 45.0%, P=.076, respectively). In multivariable analysis, positive for pelvic LN and the pure AC cell type were independent factors in both DFS and OS.
CONCLUSION: We observed that pure AC of the cervix might entail a worse survival outcome than SCC in patients with early cervical cancer (IB-IIA).
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21145099     DOI: 10.1016/j.ygyno.2010.11.022

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

1.  Increased expression of iASPP correlates with poor prognosis in FIGO IA2-IIA cervical adenocarcinoma following a curative resection.

Authors:  Fanming Kong; Xiaofeng Shi; Huzi Li; Pu Li; Jianchun Yu; XiaoJiang Li; Jun Chen; Yiyu Sun; Yingjie Jia
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

2.  A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer.

Authors:  Xiuzhen Xie; Kun Song; Baoxia Cui; Jie Jiang; Xingsheng Yang; Beihua Kong
Journal:  Int J Clin Oncol       Date:  2018-01-03       Impact factor: 3.402

3.  Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis.

Authors:  Juan Zhou; San-Gang Wu; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Qiong-Hua Chen; Zhen-Yu He
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-19       Impact factor: 4.553

Review 4.  Adenocarcinoma of the cervix: should we treat it differently?

Authors:  Ned L Williams; Theresa L Werner; Elke A Jarboe; David K Gaffney
Journal:  Curr Oncol Rep       Date:  2015-04       Impact factor: 5.075

5.  Quantitative Proteomic Analysis of Cervical Cancer Tissues Identifies Proteins Associated With Cancer Progression.

Authors:  Alberto Ramírez-Torres; Jeovanis Gil; Sandra Contreras; Graciela Ramírez; Heriberto A Valencia-González; Emmanuel Salazar-Bustamante; Leopoldo Gómez-Caudillo; Alejandro García-Carranca; Sergio Encarnación-Guevara
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

6.  Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.

Authors:  Alexi A Wright; Brooke E Howitt; Andrea P Myers; Suzanne E Dahlberg; Emanuele Palescandolo; Paul Van Hummelen; Laura E MacConaill; Melina Shoni; Nikhil Wagle; Robert T Jones; Charles M Quick; Anna Laury; Ingrid T Katz; William C Hahn; Ursula A Matulonis; Michelle S Hirsch
Journal:  Cancer       Date:  2013-08-23       Impact factor: 6.860

7.  FoxP3(+) and IL-17(+) cells are correlated with improved prognosis in cervical adenocarcinoma.

Authors:  Simone Punt; Marjolein E van Vliet; Vivian M Spaans; Cornelis D de Kroon; Gert Jan Fleuren; Arko Gorter; Ekaterina S Jordanova
Journal:  Cancer Immunol Immunother       Date:  2015-03-21       Impact factor: 6.968

8.  Intermediate-risk grouping of cervical cancer patients treated with radical hysterectomy: a Korean Gynecologic Oncology Group study.

Authors:  S Y Ryu; M H Kim; B H Nam; T S Lee; E S Song; C Y Park; J W Kim; Y B Kim; H S Ryu; S Y Park; K T Kim; C H Cho; C Lee; S M Kim; B G Kim; D S Bae; Y T Kim; J-H Nam
Journal:  Br J Cancer       Date:  2013-12-19       Impact factor: 7.640

9.  HLA-E expression in cervical adenocarcinomas: association with improved long-term survival.

Authors:  Vivian M Spaans; Alexander A W Peters; Gert Jan Fleuren; Ekaterina S Jordanova
Journal:  J Transl Med       Date:  2012-09-04       Impact factor: 5.531

10.  Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma.

Authors:  Jung-Yun Lee; Young Tae Kim; Sunghoon Kim; Boram Lee; Myong Cheol Lim; Jae-Weon Kim; Young-Joo Won
Journal:  PLoS One       Date:  2015-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.